{"nct_id": "NCT04687176", "age": "Adults", "cancer_center_accrual_goal_upper": 0, "data_table4": "Interventional", "drug_list": {"drug": [{"drug_name": "Drug: Oral Arsenic Trioxide Formulation"}]}, "long_title": "Frontline Oral Arsenic Trioxide-based Induction in Newly Diagnosed Acute Promyelocytic Leukaemia", "management_group_list": {"management_group": [{"is_primary": "Y", "management_group_name": "Group1"}]}, "oncology_group_list": {"oncology_group": [{"group_name": "Group1", "is_primary": "N"}]}, "phase": "PHASE2", "principal_investigator": "", "principal_investigator_institution": "The University of Hong Kong", "program_area_list": {"program_area": [{"is_primary": "Y", "program_area_name": "Program1"}]}, "protocol_id": 0, "protocol_no": "", "protocol_target_accrual": 100, "protocol_type": "INTERVENTIONAL", "prior_treatment_requirements": ["Inclusion Criteria:", "1. Newly diagnosed APL with t(15;17)(q24;q21) or acute myeloid leukaemia (AML) with variant RARA translocation according to the World Health Organization (WHO) Classification 2022", "2. Ability and willingness to comply with the study procedures and restrictions", "3. Voluntary written informed consent", "Exclude - Exclusion Criteria:", "Exclude - 1. ECOG performance score \\>2", "Exclude - 2. Decompensated heart failure with left-ventricular ejection fraction of less than 40% and global hypokinesia on echocardiogram.", "Exclude - 3. Prolonged corrected QT interval (QTc) \u2265 500ms, in the absence of electrolyte disturbances and medications known to prolong QTc", "Exclude - 4. Significant liver function derangement (Bilirubin \\> 3 times upper limit normal and/or ALT \\> 5 times upper limit of normal)", "Exclude - 5. Glomerular filtration rate (GRF) by Cockcroft-Gault formula or eGFR (MDRD) of less than 30mL/min in adults (aged \u2265 18) or Creatinine clearance \\< 50ml/min/1.73m2 in paediatric and adolescent patients (Age \u2264 17)", "Exclude - 6. Female subject who is lactating or has positive pregnancy test result prior to the first dose of study drug"], "short_title": "Frontline Oral Arsenic Trioxide for APL", "site_list": {"site": []}, "sponsor_list": {"sponsor": [{"is_principal_sponsor": "Y", "sponsor_name": "The University of Hong Kong", "sponsor_protocol_no": "", "sponsor_roles": "sponsor"}]}, "staff_list": {"protocol_staff": []}, "status": "open to accrual", "summary": "The investigators have formulated an oral preparation of arsenic trioxide (oral-ATO), and shown that it is efficacious for APL in R1, inducing CR2 in more than 90% of patients \\[8,9\\]. Furthermore, in an effort to prevent relapse, the investigators have moved oral-ATO forward to the maintenance of CR1. This strategy results in favorable overall-survival (OS) and leukemia-free-survival (LFS) \\[10\\], implying that prolonged treatment with oral-ATO may prevent relapses.\n\nCurrent protocols have incorporated i.v.-ATO in the treatment of newly-diagnosed APL \\[11-15\\]. For regimens comprising oral-ATO, ATRA and chemotherapy, 5-year OS in excess of 90% is achieved \\[11-15\\].\n\nThe investigators have also published long-term data showing the use of oral-ATO is highly effective and safe in the relapsed and frontline settings \\[16,17\\].\n\nIn this study, the investigators evaluate the use of oral-ATO and ATRA based induction regimens in newly diagnosed patients with APL with no of minimal chemotherapy in a prospective multicentre phase 2 study.", "treatment_list": {"step": [{"arm": [{"arm_code": "Oral arsenic trioxide, all-trans-retinoic acid, ascorbic acid (AAA)", "arm_internal_id": 0, "arm_description": "Induction: Oral arsenic trioxide 10mg daily (0.16mg/kg/day in patients \\< 18 years-old, all-trans retinoic acid (ATRA) \\[45mg/m\\^2 (25mg/m\\^2 per day in patients \\< 18 years-old) in 2 divided doses) and ascorbic acid 1g daily (15mg/kg/day in patients \\< 18 years-old) for 42 days Consolidation: Oral arsenic trioxide daily, ATRA, and ascorbic acid daily for 14 days every 28 days for 2 cycles.\n\nMaintenance: Oral arsenic trioxide, ATRA and ascorbic acid daily for 2 weeks every 8 weeks for a total of 2 years (i.e. for 12 cycles in total).", "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Drug: Oral Arsenic Trioxide Formulation", "level_internal_id": 0, "level_suspended": "N"}]}], "match": [{"and": [{"clinical": {"oncotree_primary_diagnosis": "", "disease_status": ["", ""]}}, {"genomic": {"hugo_symbol": "", "variant_category": ""}}]}]}]}}